Maximal Effort Cytoreduction in Epithelial Ovarian Cancer: Perioperative Complications and Survival Outcomes from a Retrospective Cohort
Open Access
- 12 January 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (2) , 622
Abstract
Background: Rates of maximal effort cytoreductive surgery in ovarian cancer patients increase gradually the last decade. The purpose of the present study is to evaluate factors that contribute to survival and morbidity outcomes in this group of patients. Methods: We retrospectively reviewed patient records of epithelial ovarian cancer patients with an intermediate and high Mayo Clinic surgical complexity score, operated between January 2010 and December 2018. Results: Overall, 107 patients were enrolled in the present study with a median age of 62 years (23–84) and a follow-up of 32 months (2–156). Thirteen Clavien-Dindo grade IIIa complications were documented in 10 patients (9.3%). Of all the investigated factors, only stage IVb (p = 0.027) and interval debulking surgery (p = 0.042) affected overall survival rates. Overall survival outcomes of patients operated on a primary setting started to differentiate compared to those that received neo-adjuvant chemotherapy after the 4th postoperative year. Conclusions: Maximal effort cytoreductive procedures should be considered feasible in the modern surgical era, as they are accompanied by acceptable rates of perioperative morbidity. Hence, every effort should be made to perform them in the primary setting, rather than following neoadjuvant chemotherapy as current evidence favor increased survival rates of patients that will likely surpass an interval of observation of more than 4 years.Keywords
This publication has 26 references indexed in Scilit:
- Ovarian cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilitiesArchives of Gynecology and Obstetrics, 2016
- Anti-angiogenic agents in ovarian cancer: past, present, and futureAnnals of Oncology, 2016
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV DiseaseAnnals of Surgical Oncology, 2010
- Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic ExperienceJournal of the American College of Surgeons, 2009
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2007
- Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approachGynecologic Oncology, 2004
- „IMO” - Intraoperatives Mapping des OvarialkarzinomsZentralblatt Fur Gynakologie, 2003